Risk of cardiovascular events among patients with HIV treated with atazanavir-containing regimens: a retrospective cohort study

Table 1 Patient attrition for antiretroviral-naïve HIV+ patients initiating atazanavir-containing vs. atazanavir-free regimens

Criterion	Commercial Database	Medicaid Database
Patients with ≥1 prescription for an ARV medication^a between 1/1/2007 and 12/31/2013 (first claim = index date)	98,672	31,806
AND age 18–64 at index date	97,911	29,782
AND continuous enrollment for ≥6 months prior to index date	36,942	13,197
AND no eligibility for Medicare	36,942	13,181
AND no claims for ARV medications prior to index date^b	26,958	7,731
AND ≥1 claim with an HIV diagnosis prior to index date^b	22,285	7,185
AND no CV event^c in the 6 months prior to index date	22,211	7,136
Final Study Population	22,211	7,136
Initiated ATV-containing regimen	2,437	1,505
Initiated ATV-free regimen	19,774	5,631
Initiated PI-free regimen	16,131	3,931
Initiated other PI-containing regimen	3,643	1,700
Initiated DRV-containing regimen	1,551	527

ARV antiretroviral, ATV atazanavir, DRV darunavir, CV cardiovascular, PI protease inhibitor
^aARV medications included non-nucleoside reverse transcriptase inhibitors, protease inhibitors (excluding ritonavir), integrase inhibitors, fusion inhibitors and CCR5 antagonists. ^bUsing all data prior to index date starting with 2004. ^cMyocardial infarction, stroke, percutaneous coronary intervention, or coronary artery bypass graft

ISSN: 1471-2334